Stonepine Capital Management LLC Trims Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Stonepine Capital Management LLC trimmed its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 51.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 839,514 shares of the company's stock after selling 880,486 shares during the period. Atea Pharmaceuticals accounts for approximately 1.1% of Stonepine Capital Management LLC's holdings, making the stock its 12th largest position. Stonepine Capital Management LLC owned about 1.01% of Atea Pharmaceuticals worth $2,561,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Advisor Group Holdings Inc. increased its stake in shares of Atea Pharmaceuticals by 78.8% in the 1st quarter. Advisor Group Holdings Inc. now owns 4,070 shares of the company's stock worth $28,000 after purchasing an additional 1,794 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Atea Pharmaceuticals by 26.7% in the 1st quarter. Lazard Asset Management LLC now owns 10,908 shares of the company's stock worth $78,000 after buying an additional 2,298 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Atea Pharmaceuticals by 16.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 17,107 shares of the company's stock worth $121,000 after buying an additional 2,410 shares during the period. Royal Bank of Canada boosted its holdings in Atea Pharmaceuticals by 123.6% in the 3rd quarter. Royal Bank of Canada now owns 4,536 shares of the company's stock worth $26,000 after buying an additional 2,507 shares during the period. Finally, Osaic Holdings Inc. boosted its holdings in Atea Pharmaceuticals by 93.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,154 shares of the company's stock worth $27,000 after buying an additional 3,453 shares during the period. 86.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Atea Pharmaceuticals news, insider Andrea Corcoran sold 15,843 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.84, for a total transaction of $60,837.12. Following the completion of the transaction, the insider now owns 670,208 shares of the company's stock, valued at approximately $2,573,598.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Atea Pharmaceuticals news, insider Andrea Corcoran sold 15,843 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.84, for a total transaction of $60,837.12. Following the completion of the transaction, the insider now owns 670,208 shares of the company's stock, valued at approximately $2,573,598.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Wayne Foster sold 12,477 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.84, for a total transaction of $47,911.68. Following the transaction, the chief accounting officer now directly owns 20,857 shares of the company's stock, valued at approximately $80,090.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 85,230 shares of company stock valued at $327,852. Company insiders own 14.50% of the company's stock.

Atea Pharmaceuticals Trading Up 1.3 %

Atea Pharmaceuticals stock traded up $0.05 during mid-day trading on Tuesday, hitting $3.81. The stock had a trading volume of 116,700 shares, compared to its average volume of 459,765. The firm has a market capitalization of $320.69 million, a P/E ratio of -2.32 and a beta of 0.16. The firm's 50 day moving average is $4.07 and its 200 day moving average is $3.47. Atea Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $5.19.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.03). As a group, equities research analysts forecast that Atea Pharmaceuticals, Inc. will post -2.76 earnings per share for the current year.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.

Want to see what other hedge funds are holding AVIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.